Apellis Pharmaceuticals (APLS) PT Raised to $26 at RBC Capital
Tweet Send to a Friend
RBC Capital analyst Lisa Walter raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $26.00 (from $24.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
